Skip to content

Intervention Study for Individuals With Compulsive Sexual Behavior

Sexual Risk Behavior, Clinical and Psychopathological Aspects of Individuals With Compulsive Sexual Behavior of the Institute of Psychiatry of the General Hospital of the University of São Paulo Medical School, an Intervention Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02300051
Enrollment
135
Registered
2014-11-24
Start date
2011-02-28
Completion date
2015-07-31
Last updated
2015-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compulsive Sexual Behavior

Keywords

Compulsive sexual behavior, Intervention, Short term psychodynamic group psychotherapy, Sexual addiction, Hypersexual behavior

Brief summary

The purpose of this study is compare three interventions (short-term psychodynamic psychotherapeutic group and relapse prevention group therapy vs. treatment as usual, namely, psychiatric follow up including prescription of medication vs. both interventions combined) to individuals presenting compulsive sexual behavior.

Detailed description

We will compare three groups of patients under the three interventions, namely, (1) Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by Relapse Prevention Group Therapy (RPGT) (n = 48) vs. (2) Treatment as Usual (TAU) (n = 42) vs. (3) both previous interventions combined (n = 45). The STPGP is a 16 weekly session's group psychotherapy. Each session lasts 90 minutes. Each group will consist of around 10 participants. All the groups of STPGP will be conducted by the same psychotherapist. The RPGT is an eight weekly therapy group. The sessions are structured and will last 90 minutes. The medication used by those who are under TAU will be introduced through psychiatric care. Initially three visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine, paroxetine, sertraline) or mood stabilizers (topiramate, divalproex sodium, oxcarbazepine) or both type of medications combined. All patients will be assessed on the outcomes and independent variables in the baseline (time 0); in the 25th week (time 1); and 34th week (time 2) of treatment.

Interventions

BEHAVIORALSTPGP and RPGT
DRUGTAU

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. meeting the criteria for excessive sexual drive (ICD-10 F52.7) which corresponds to complain of an excessive sexual drive that often leads to out of control sexual behaviors AND meeting the criteria for sex addiction by Goodman (2001), which is characterized as a maladaptive pattern of sexual behavior leading to clinically impairment or distress as manifested in the same 12-month period by three or more of the following: tolerance (process of engaging in increasingly sexual behavior, in terms of intensity and frequency to obtain the same satisfaction than before); withdrawal (experience of abstinence, characterized by the presence of physical and/or psychological symptoms, when the behavior is diminished or discontinued); frequent sexual behavior; unsuccessful efforts to control it; many time spent in preparation for it; social or occupational activities are diminished because of it; it goes on despite negative outcomes; 2. being literate in Portuguese; 3. cognitive ability to answer self-responsive measures.

Exclusion criteria

- individuals who met criteria for: 1. sexual preference disorders (ICD-10 F65); 2. manic or hypomanic state of bipolar disorder (ICD-10 F30.0, F31.0, 31.1, and 31.2); 3. schizophrenia, schizotypal, and delusional disorders (ICD-10 F20 - F29); 4. other mental disorders due to brain dysfunction, injury or physical disease (ICD-10 F06); 5. gender identity disorder (ICD-10 F64).

Design outcomes

Primary

MeasureTime frameDescription
Sexual Compulsivity Scale (SCS)Baseline, 25th and 34th weekChanges in the total score of SCS

Secondary

MeasureTime frameDescription
World Health Organization Quality of Life (WHOQOL-bref)Baseline and 25th weekChanges in the WHOQOL-bref scores.

Other

MeasureTime frameDescription
Proportion of use of condom when engaging in anal and vaginal sexual intercourse, number of casual partnersBaseline, 25th, and 34th weekChanges in proportions of use of condom when engaging in anal and vaginal sexual intercourse, and number of casual partners reported
Beck Anxiety Inventory (BAI)Baseline and 25th weekChanges in BAI scores
Barratt Impulsivity Scale (BIS) 11Baseline, 25th, and 34th weekChanges in BIS 11 scores
Adult Attachment Scale (AAS)Baseline, and 25th weekChanges in AAS scores
Knowledge and Perceptions regarding HIV transmissionBaseline, 25th week, and 34th week.Changes in proportion of knowledge and perceptions on HIV transmission.
Wisconsin Card Sorting Test (WCST)Baseline, and 25th weekChanges in scores of the neurocognitive task.
Continuous Performance Test (CPT)Baseline, and 25th weekChanges in scores of the neurocognitive task.
Medication adverse effect record25th weekInvestigation of medical records on adverse effect
Beck Depression Inventory (BDI)Baseline and 25th weekChanges in BDI scores

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026